BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 30957954)

  • 21. Histamine H3-receptor inverse agonists as novel antipsychotics.
    Ito C
    Cent Nerv Syst Agents Med Chem; 2009 Jun; 9(2):132-6. PubMed ID: 20021346
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacological characterization of seven human histamine H
    Gao M; Dekker ME; Leurs R; Vischer HF
    Eur J Pharmacol; 2024 Apr; 968():176450. PubMed ID: 38387718
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Discovery of novel steroidal histamine H
    Ledneczki I; Tapolcsányi P; Gábor E; Éles J; Greiner I; Schmidt É; Némethy Z; Kedves RS; Balázs O; Román V; Lévay G; Mahó S
    Bioorg Med Chem Lett; 2017 Oct; 27(19):4525-4530. PubMed ID: 28888822
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Discovery and characterization of 6-{4-[3-(R)-2-methylpyrrolidin-1-yl)propoxy]phenyl}-2H-pyridazin-3-one (CEP-26401, irdabisant): a potent, selective histamine H3 receptor inverse agonist.
    Hudkins RL; Raddatz R; Tao M; Mathiasen JR; Aimone LD; Becknell NC; Prouty CP; Knutsen LJ; Yazdanian M; Moachon G; Ator MA; Mallamo JP; Marino MJ; Bacon ER; Williams M
    J Med Chem; 2011 Jul; 54(13):4781-92. PubMed ID: 21634396
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The evolution of histamine H₃ antagonists/inverse agonists.
    Lebois EP; Jones CK; Lindsley CW
    Curr Top Med Chem; 2011; 11(6):648-60. PubMed ID: 21261594
    [TBL] [Abstract][Full Text] [Related]  

  • 26. From ergolines to indoles: improved inhibitors of the human H3 receptor for the treatment of narcolepsy.
    Auberson YP; Troxler T; Zhang X; Yang CR; Feuerbach D; Liu YC; Lagu B; Perrone M; Lei L; Shen X; Zhang D; Wang C; Wang TL; Briner K; Bock MG
    ChemMedChem; 2015 Feb; 10(2):266-75. PubMed ID: 25394333
    [TBL] [Abstract][Full Text] [Related]  

  • 27. (11)C-MK-8278 PET as a tool for pharmacodynamic brain occupancy of histamine 3 receptor inverse agonists.
    Van Laere KJ; Sanabria-Bohórquez SM; Mozley DP; Burns DH; Hamill TG; Van Hecken A; De Lepeleire I; Koole M; Bormans G; de Hoon J; Depré M; Cerchio K; Plalcza J; Han L; Renger J; Hargreaves RJ; Iannone R
    J Nucl Med; 2014 Jan; 55(1):65-72. PubMed ID: 24263088
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Synthesis and biological activity of novel tert-butyl and tert-pentylphenoxyalkyl piperazine derivatives as histamine H
    Szczepańska K; Karcz T; Mogilski S; Siwek A; Kuder KJ; Latacz G; Kubacka M; Hagenow S; Lubelska A; Olejarz A; Kotańska M; Sadek B; Stark H; Kieć-Kononowicz K
    Eur J Med Chem; 2018 May; 152():223-234. PubMed ID: 29723785
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Discovery of a potent, selective, and orally bioavailable histamine H3 receptor antagonist SAR110068 for the treatment of sleep-wake disorders.
    Gao Z; Hurst WJ; Czechtizky W; Francon D; Griebel G; Nagorny R; Pichat P; Schwink L; Stengelin S; Hendrix JA; George PG
    Bioorg Med Chem Lett; 2013 Nov; 23(22):6141-5. PubMed ID: 24076172
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In vivo pharmacological profile of S 38093, a novel histamine H3 receptor inverse agonist.
    Panayi F; Sors A; Bert L; Martin B; Rollin-Jego G; Billiras R; Carrié I; Albinet K; Danober L; Rogez N; Thomas JY; Pira L; Bertaina-Anglade V; Lestage P
    Eur J Pharmacol; 2017 May; 803():1-10. PubMed ID: 28315340
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Several down, a few to go: histamine H3 receptor ligands making the final push towards the market?
    Kuhne S; Wijtmans M; Lim HD; Leurs R; de Esch IJ
    Expert Opin Investig Drugs; 2011 Dec; 20(12):1629-48. PubMed ID: 21992603
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Discovery of aryl ureas and aryl amides as potent and selective histamine H3 receptor antagonists for the treatment of obesity (part II).
    Gao Z; Hurst WJ; Guillot E; Czechtizky W; Lukasczyk U; Nagorny R; Pruniaux MP; Schwink L; Sanchez JA; Stengelin S; Tang L; Winkler I; Hendrix JA; George PG
    Bioorg Med Chem Lett; 2013 Jun; 23(11):3421-6. PubMed ID: 23591112
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacological and SAR analysis of the LINS01 compounds at the human histamine H
    Corrêa MF; Barbosa ÁJR; Fernandes GAB; Baker JG; Fernandes JPDS
    Chem Biol Drug Des; 2019 Jan; 93(1):89-95. PubMed ID: 30153371
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Two novel and selective nonimidazole histamine H3 receptor antagonists A-304121 and A-317920: I. In vitro pharmacological effects.
    Esbenshade TA; Krueger KM; Miller TR; Kang CH; Denny LI; Witte DG; Yao BB; Fox GB; Faghih R; Bennani YL; Williams M; Hancock AA
    J Pharmacol Exp Ther; 2003 Jun; 305(3):887-96. PubMed ID: 12606603
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identification of the antiarrhythmic drugs amiodarone and lorcainide as potent H3 histamine receptor inverse agonists.
    Del Tredici AL; Ma JN; Piu F; Burstein ES
    J Pharmacol Exp Ther; 2014 Jan; 348(1):116-24. PubMed ID: 24204014
    [TBL] [Abstract][Full Text] [Related]  

  • 36. 3,4-Diaza-bicyclo[4.1.0]hept-4-en-2-one phenoxypropylamine analogs of irdabisant (CEP-26401) as potent histamine-3 receptor inverse agonists with robust wake-promoting activity.
    Hudkins RL; Becknell NC; Lyons JA; Aimone LD; Olsen M; Haltiwanger RC; Mathiasen JR; Raddatz R; Gruner JA
    Eur J Med Chem; 2015 May; 95():349-56. PubMed ID: 25827402
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Role of hydrophobic substituents on the terminal nitrogen of histamine in receptor binding and agonist activity: development of an orally active histamine type 3 receptor agonist and evaluation of its antistress activity in mice.
    Ishikawa M; Shinei R; Yokoyama F; Yamauchi M; Oyama M; Okuma K; Nagayama T; Kato K; Kakui N; Sato Y
    J Med Chem; 2010 May; 53(9):3840-4. PubMed ID: 20384344
    [TBL] [Abstract][Full Text] [Related]  

  • 38. SAR exploration of the non-imidazole histamine H
    Wágner G; Mocking TAM; Ma X; Slynko I; Da Costa Pereira D; Breeuwer R; Rood NJN; van der Horst C; Vischer HF; de Graaf C; de Esch IJP; Wijtmans M; Leurs R
    Arch Pharm (Weinheim); 2023 Jan; 356(1):e2200451. PubMed ID: 36310109
    [TBL] [Abstract][Full Text] [Related]  

  • 39. 2-(Pyrrolidin-1-yl)ethyl-3,4-dihydroisoquinolin-1(2H)-one derivatives as potent and selective histamine-3 receptor antagonists.
    Zhou D; Gross JL; Adedoyin AB; Aschmies SB; Brennan J; Bowlby M; Di L; Kubek K; Platt BJ; Wang Z; Zhang G; Brandon N; Comery TA; Robichaud AJ
    J Med Chem; 2012 Mar; 55(5):2452-68. PubMed ID: 22313242
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Progress in the development of histamine H
    Łażewska D; Kieć-Kononowicz K
    Expert Opin Ther Pat; 2018 Mar; 28(3):175-196. PubMed ID: 29334795
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.